Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably th...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-11, Vol.16 (32), p.2595-2609 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2609 |
|---|---|
| container_issue | 32 |
| container_start_page | 2595 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Mano, Max |
| description | Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC. |
| doi_str_mv | 10.2217/fon-2020-0219 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2473446915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473446915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-ab46114d6daf4c8c8700c6a025c310a7f19b78da8ebb1705759a7e36d27869a43</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlaPXiXgOZqvTTbeRKpVCoLUc5jNZuuW7m5NdoX6601p9eZpZuCZd5gHoUtGbzhn-rbqWsIpp4RyZo7QmGkpSS4oO0691IYoZeQIncW4olRqkdFTNBJcC6m1GaOXRYDYD99DAwX2TQ9trFt_hwEvofHYfUC79AHXLZ5N3zjZdLHu6y-PPYT1FhfBp23soHU-nKOTCtbRXxzqBL0_ThcPMzJ_fXp-uJ8TJzTrCRRSMSZLVUIlXe5yTalTQHnmBKOgK2YKnZeQ-6JgmmY6M6C9UCXXuTIgxQRd73M3ofscfOztqhtCm05anh6UUhmWJYrsKRe6GIOv7CbUDYStZdTuzNlkzu7M2Z25xF8dUoei8eUf_asqAWYPVEM_BB9d7dPXdj-ljdolcf-E_wDsV3vH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473446915</pqid></control><display><type>article</type><title>Trastuzumab emtansine: a game changer in HER2-positive early breast cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Mano, Max</creator><creatorcontrib>Mano, Max</creatorcontrib><description>Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0219</identifier><identifier>PMID: 32734779</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Ado-Trastuzumab Emtansine - administration & dosage ; Ado-Trastuzumab Emtansine - adverse effects ; Ado-Trastuzumab Emtansine - therapeutic use ; Antibodies ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Cancer therapies ; Chemotherapy ; Clinical trials ; Clinical Trials as Topic ; Combined Modality Therapy ; Cytotoxicity ; early breast cancer ; FDA approval ; Female ; Humans ; Immunotherapy ; Metastasis ; Monoclonal antibodies ; Neoadjuvant Therapy ; pathological complete response ; Receptor, ErbB-2 - antagonists & inhibitors ; Receptor, ErbB-2 - metabolism ; Regulatory approval ; T-DM1 ; Targeted cancer therapy ; trastuzumab ; trastuzumab emtansine ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609</ispartof><rights>2020 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Nov 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-ab46114d6daf4c8c8700c6a025c310a7f19b78da8ebb1705759a7e36d27869a43</citedby><cites>FETCH-LOGICAL-c371t-ab46114d6daf4c8c8700c6a025c310a7f19b78da8ebb1705759a7e36d27869a43</cites><orcidid>0000-0001-5666-5261</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32734779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mano, Max</creatorcontrib><title>Trastuzumab emtansine: a game changer in HER2-positive early breast cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.</description><subject>Ado-Trastuzumab Emtansine - administration & dosage</subject><subject>Ado-Trastuzumab Emtansine - adverse effects</subject><subject>Ado-Trastuzumab Emtansine - therapeutic use</subject><subject>Antibodies</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>Cytotoxicity</subject><subject>early breast cancer</subject><subject>FDA approval</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Neoadjuvant Therapy</subject><subject>pathological complete response</subject><subject>Receptor, ErbB-2 - antagonists & inhibitors</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Regulatory approval</subject><subject>T-DM1</subject><subject>Targeted cancer therapy</subject><subject>trastuzumab</subject><subject>trastuzumab emtansine</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlaPXiXgOZqvTTbeRKpVCoLUc5jNZuuW7m5NdoX6601p9eZpZuCZd5gHoUtGbzhn-rbqWsIpp4RyZo7QmGkpSS4oO0691IYoZeQIncW4olRqkdFTNBJcC6m1GaOXRYDYD99DAwX2TQ9trFt_hwEvofHYfUC79AHXLZ5N3zjZdLHu6y-PPYT1FhfBp23soHU-nKOTCtbRXxzqBL0_ThcPMzJ_fXp-uJ8TJzTrCRRSMSZLVUIlXe5yTalTQHnmBKOgK2YKnZeQ-6JgmmY6M6C9UCXXuTIgxQRd73M3ofscfOztqhtCm05anh6UUhmWJYrsKRe6GIOv7CbUDYStZdTuzNlkzu7M2Z25xF8dUoei8eUf_asqAWYPVEM_BB9d7dPXdj-ljdolcf-E_wDsV3vH</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Mano, Max</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-5666-5261</orcidid></search><sort><creationdate>20201101</creationdate><title>Trastuzumab emtansine: a game changer in HER2-positive early breast cancer</title><author>Mano, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-ab46114d6daf4c8c8700c6a025c310a7f19b78da8ebb1705759a7e36d27869a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ado-Trastuzumab Emtansine - administration & dosage</topic><topic>Ado-Trastuzumab Emtansine - adverse effects</topic><topic>Ado-Trastuzumab Emtansine - therapeutic use</topic><topic>Antibodies</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>Cytotoxicity</topic><topic>early breast cancer</topic><topic>FDA approval</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Neoadjuvant Therapy</topic><topic>pathological complete response</topic><topic>Receptor, ErbB-2 - antagonists & inhibitors</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Regulatory approval</topic><topic>T-DM1</topic><topic>Targeted cancer therapy</topic><topic>trastuzumab</topic><topic>trastuzumab emtansine</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mano, Max</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mano, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trastuzumab emtansine: a game changer in HER2-positive early breast cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>16</volume><issue>32</issue><spage>2595</spage><epage>2609</epage><pages>2595-2609</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32734779</pmid><doi>10.2217/fon-2020-0219</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5666-5261</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_journals_2473446915 |
| source | MEDLINE; PubMed Central |
| subjects | Ado-Trastuzumab Emtansine - administration & dosage Ado-Trastuzumab Emtansine - adverse effects Ado-Trastuzumab Emtansine - therapeutic use Antibodies Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer therapies Chemotherapy Clinical trials Clinical Trials as Topic Combined Modality Therapy Cytotoxicity early breast cancer FDA approval Female Humans Immunotherapy Metastasis Monoclonal antibodies Neoadjuvant Therapy pathological complete response Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - metabolism Regulatory approval T-DM1 Targeted cancer therapy trastuzumab trastuzumab emtansine Treatment Outcome |
| title | Trastuzumab emtansine: a game changer in HER2-positive early breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A27%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trastuzumab%20emtansine:%20a%20game%20changer%20in%20HER2-positive%20early%20breast%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Mano,%20Max&rft.date=2020-11-01&rft.volume=16&rft.issue=32&rft.spage=2595&rft.epage=2609&rft.pages=2595-2609&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0219&rft_dat=%3Cproquest_cross%3E2473446915%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473446915&rft_id=info:pmid/32734779&rfr_iscdi=true |